Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 1,79 € (+1.391,67 %). Medianen er 1,79 € (+1.391,67 %).

Køb
  8
Behold
  4
Sælg
  1

  • Accuray reports mixed Q4 results: revenue weaker, stock under pressure

    Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » Mere på de.investing.com


  • Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence

    Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » Mere på de.investing.com


  • Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs

    Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » Mere på de.investing.com

I 2022 har Accuray allerede udloddet 0,62 € i udbytte. Den seneste udlodning fandt sted i juni 2022.

Virksomhedstal

I det seneste kvartal havde Accuray en omsætning på 88,43 mio. € og et nettoresultat på -1,7 mio. €
(EUR) juni 2026
YoY
Omsætning 88,43 mio. 18,28 %
Bruttofortjeneste 31,14 mio. 5,84 %
Nettoresultat -1,7 mio. 278,50 %
EBITDA 8,08 mio. 20,56 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
14,85 mio. €
Antal aktier
119,44 mio.
Højeste/laveste i 52 uger
1,31 € - 0,11 €
Udbytte Nej
Beta
1,42
P/E (PE Ratio)
-0,35
PEG (PEG Ratio)
0,00
K/I (PB Ratio)
0,41
P/S (PS Ratio)
0,04

Virksomhedsprofil

Accuray Incorporated designer, udvikler, fremstiller og sælger strålekirurgi- og strålebehandlingssystemer til behandling af tumorer i Amerika, Europa, Mellemøsten, Indien, Afrika, Japan, Kina og resten af Asien-Stillehavsregionen. Selskabet tilbyder CyberKnife-systemet, et robotbaseret system til stereotaktisk strålekirurgi og stereotaktisk kropsstrålebehandling, der anvendes til behandling af forskellige typer kræft og tumorer i kroppen, såsom prostata, lunger, hjerne, rygsøjle, lever, bugspytkirtel og nyre. Selskabet leverer desuden TomoTherapy-systemet, herunder Radixact-systemet, som er et integreret strålebehandlingssystem designet til behandling af en række kræftformer. Derudover tilbyder selskabet kundesupport efter kontrakt, installation, uddannelse og andre professionelle serviceydelser. Selskabet markedsfører sine produkter primært direkte til kunder, herunder hospitaler og selvstændige behandlingsfaciliteter gennem sin salgsorganisation, samt til kunder gennem salgsagenter og indkøbsorganisationer i USA; og til kunder direkte og gennem distributører og salgsagenter internationalt. Accuray Incorporated blev stiftet i 1990 og har hovedkontor i Sunnyvale, Californien.

Navn
Accuray
CEO
Stephen R. LaNeve
Hjemsted Madison, wi
USA
Websted
Sektor
Cykliske forbrugsvarer
Branche
Forbrugsgoder
Børsnotering
08.02.2007
Medarbejdere 809

Tickersymboler

Børs Symbol
NASDAQ
ARAY
London Stock Exchange
0H8I.L
Frankfurt
XEJ.F
Düsseldorf
XEJ.DU
London
0H8I.L
SIX
XEJ.SW
München
XEJ.MU
🍪

Parqet  bruger cookies. Læs mere